Objective:To study the effect of telmisartan combined with lipid-lowering drug therapy on serum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellitus complicated by coronary heart diseas...Objective:To study the effect of telmisartan combined with lipid-lowering drug therapy on serum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellitus complicated by coronary heart disease.Methods:A total of106 patients with type 2 diabetes mellitus complicated by coronary heart disease who were treated in our hospital between September 2013 and October 2016 were collected and then divided into the control group (n=55) who received conventional treatment + lipid-lowering drug treatment and the observation group (n=51) who received conventional treatment + lipid-lowering drug + telmisartan treatment after the therapies were reviewed. Before and after treatment, serum levels of lipid metabolism indexes, inflammatory mediators and oxidative stress indexes were compared between two groups of patients.Results:Before treatment, the differences in serum levels of lipid metabolism indexes, inflammatory mediators and oxidative stress indexes were not statistically significant between two groups of patients. After treatment, serum TG and LDL-C levels in observation group were lower than those in control group while HDL-C level was higher than that in control group;serum inflammatory mediators IL-6, IL-8, HMGB1 and TNF-α levels were lower than those in control group;serum oxidative stress indexes MDA and ROS levels were lower than those in control group while GSH-Px level was higher than that in control group.Conclusion:Telmisartan combined with lipid-lowering drug therapy can effectively optimize the lipid metabolism and reduce the systemic inflammatory response and oxidative stress response in patients with type 2 diabetes mellitus complicated by coronary heart disease.展开更多
Crosstalk between lipid peroxidation and inflammation is known to be a pathognomonic feature for the development of coronary heart disease(CHD).In this regard ligand activated liver X receptor(LXR)-α has emerged as a...Crosstalk between lipid peroxidation and inflammation is known to be a pathognomonic feature for the development of coronary heart disease(CHD).In this regard ligand activated liver X receptor(LXR)-α has emerged as a key molecular switch by its inherent ability to modulate an array of genes involved in these two fundamental cellular processes.In addition,LXR-α has also been found to play a role in hepatic lipogenesis and innate immunity.Although several lines of evidence in experimental model systems have established the atheroprotective nature of LXR-α,human subjects have been reported to possess a paradoxical situation in which increased blood cellular LXR-α gene expression is always accompanied by increased coronary occlusion.This apparent paradox was resolved recently by the finding that CHD patients possess a deregulated LXR-α transcriptome due to impaired ligand-receptor interaction.This blood cellular mutated LXR-α gene ex- pression correlated specifically with the extent of coro- nary occlusion and hence need is felt to devise new synthetic ligands that could restore the function of this mutated LXR-αprotein in order to modulate genes involved in reverse cholesterol transport and suppression of the inflammatory response leading to the effective treatment of CHD.展开更多
Objective:To study the correlation of CT coronary angiography plaque properties with platelet function and serum biochemical indexes in patients with coronary heart disease.Methods:Patients who received CT coronary an...Objective:To study the correlation of CT coronary angiography plaque properties with platelet function and serum biochemical indexes in patients with coronary heart disease.Methods:Patients who received CT coronary angiography examination and were diagnosed with coronary heart disease in Tianmen First People's Hospital between March 2015 and October 2017 were selected as the research subjects and divided into those with soft plaque, mixed plaque and calcified plaque according to the CT results;the serum levels of platelet function indexes as well as blood lipid and inflammation biochemical indexes were determined. Results: Serum PAF, CD62P, sTLT-1, LDL, Lp-a, PCSK9, TNF-α, IFN-γ, IL-17A, CD40L and sICAM1 levels as well as platelet surface EMMPRIN and GPVI fluorescence intensity of patients with soft plaque and mixed plaque were significantly higher than those of patients with calcified plaques whereas serum HDL levels were lower than that of patients with calcified plaque, and serum PAF, CD62P, sTLT-1, LDL, Lp-a, PCSK9, TNF-α, IFN-γ, IL-17A, CD40L and sICAM1 levels as well as platelet surface EMMPRIN and GPVI fluorescence intensity of patients with soft plaque were significantly higher than those of patients with mixed plaque whereas serum HDL level was lower than that of patients with mixed plaque. Conclusion: The changes of CT coronary angiography plaque properties in patients with coronary heart disease are closely related to platelet aggregation, lipid metabolism disorder and inflammatory response activation.展开更多
文摘Objective:To study the effect of telmisartan combined with lipid-lowering drug therapy on serum lipid metabolism index and cytokine levels in patients with type 2 diabetes mellitus complicated by coronary heart disease.Methods:A total of106 patients with type 2 diabetes mellitus complicated by coronary heart disease who were treated in our hospital between September 2013 and October 2016 were collected and then divided into the control group (n=55) who received conventional treatment + lipid-lowering drug treatment and the observation group (n=51) who received conventional treatment + lipid-lowering drug + telmisartan treatment after the therapies were reviewed. Before and after treatment, serum levels of lipid metabolism indexes, inflammatory mediators and oxidative stress indexes were compared between two groups of patients.Results:Before treatment, the differences in serum levels of lipid metabolism indexes, inflammatory mediators and oxidative stress indexes were not statistically significant between two groups of patients. After treatment, serum TG and LDL-C levels in observation group were lower than those in control group while HDL-C level was higher than that in control group;serum inflammatory mediators IL-6, IL-8, HMGB1 and TNF-α levels were lower than those in control group;serum oxidative stress indexes MDA and ROS levels were lower than those in control group while GSH-Px level was higher than that in control group.Conclusion:Telmisartan combined with lipid-lowering drug therapy can effectively optimize the lipid metabolism and reduce the systemic inflammatory response and oxidative stress response in patients with type 2 diabetes mellitus complicated by coronary heart disease.
文摘Crosstalk between lipid peroxidation and inflammation is known to be a pathognomonic feature for the development of coronary heart disease(CHD).In this regard ligand activated liver X receptor(LXR)-α has emerged as a key molecular switch by its inherent ability to modulate an array of genes involved in these two fundamental cellular processes.In addition,LXR-α has also been found to play a role in hepatic lipogenesis and innate immunity.Although several lines of evidence in experimental model systems have established the atheroprotective nature of LXR-α,human subjects have been reported to possess a paradoxical situation in which increased blood cellular LXR-α gene expression is always accompanied by increased coronary occlusion.This apparent paradox was resolved recently by the finding that CHD patients possess a deregulated LXR-α transcriptome due to impaired ligand-receptor interaction.This blood cellular mutated LXR-α gene ex- pression correlated specifically with the extent of coro- nary occlusion and hence need is felt to devise new synthetic ligands that could restore the function of this mutated LXR-αprotein in order to modulate genes involved in reverse cholesterol transport and suppression of the inflammatory response leading to the effective treatment of CHD.
文摘Objective:To study the correlation of CT coronary angiography plaque properties with platelet function and serum biochemical indexes in patients with coronary heart disease.Methods:Patients who received CT coronary angiography examination and were diagnosed with coronary heart disease in Tianmen First People's Hospital between March 2015 and October 2017 were selected as the research subjects and divided into those with soft plaque, mixed plaque and calcified plaque according to the CT results;the serum levels of platelet function indexes as well as blood lipid and inflammation biochemical indexes were determined. Results: Serum PAF, CD62P, sTLT-1, LDL, Lp-a, PCSK9, TNF-α, IFN-γ, IL-17A, CD40L and sICAM1 levels as well as platelet surface EMMPRIN and GPVI fluorescence intensity of patients with soft plaque and mixed plaque were significantly higher than those of patients with calcified plaques whereas serum HDL levels were lower than that of patients with calcified plaque, and serum PAF, CD62P, sTLT-1, LDL, Lp-a, PCSK9, TNF-α, IFN-γ, IL-17A, CD40L and sICAM1 levels as well as platelet surface EMMPRIN and GPVI fluorescence intensity of patients with soft plaque were significantly higher than those of patients with mixed plaque whereas serum HDL level was lower than that of patients with mixed plaque. Conclusion: The changes of CT coronary angiography plaque properties in patients with coronary heart disease are closely related to platelet aggregation, lipid metabolism disorder and inflammatory response activation.
